Expedite LNP Applications for Next Generation Therapeutics Beyond mRNA with Optimised Formulation, Scalability & Regulatory Compliance at Forefront of Mind
With lipid nanoparticles moving beyond mRNA vaccines, biopharma are racing against the clock to exploit clinical utility to deliver more complex payloads, while optimising scalability and product quality.
Following industry progress of BioNTech entering LNP cancer vaccine trials, Moderna entering $76m collaboration with Gen Bio, and Bayer-Acuitas Therapeutics partnership using LNP for gene therapy, the field shows no signs of slowing down.
In collaboration with CPI, Pfizer, GSK, this 3-day summit will reunite 100+ senior leaders, sharing exclusive data to help you maximise this non-viral delivery system's potential. The 2nd Lipid Nanoparticle Development Europe Summit is committed to equipping you with actionable takeaways across end-to-end characterisation, biodistribution, formulation and scale up to supercharge your LNP pipeline development with therapeutic promise to patients.
Unite in October to get ahead of the curve and exploit LNP as the hottest delivery vehicle.
2nd LNP Formulation & Process Development Event Highlights
“I am looking forward to hearing the latest developments in LNP manufacturing and characterisation, and also understanding key challenges companies have to help me plan our future offering”
Industry Leading Speakers Include:
MSAT mRNA Drug Product Expert
Team Leader & Principal Scientist, Nanopharmaceuticals
Vice President RNA Formulation & Drug Delivery